Apnoeic diffusion oxygenation has been evaluated in humans and animals since the beginning of the 20 th century, but has never served as an alternative to traditional ventilation as a result of the rapid increase of carbon dioxide (CO 2 ) and consequential decrease in pH. [1] [2] [3] [4] Recently, Transnasal Humidified
Rapid-Insufflation Ventilatory exchange (THRIVE) was used to extend the apnoeic window up to 65 min in patients with difficult airways before securing the airway. 5 None of these patients desaturated below 90%. The rate of increase in end-tidal carbon dioxide (ETCO 2 ) was 0.15 kPa min À1 , lower than earlier findings of an increase in ETCO 2 or arterial carbon dioxide (PaCO 2 ) of approximately 0.5 kPa min À1 , 2 6-8 which indicates partial gas exchange. 5 With this mass flow of oxygen into an open airway there are speculations that some amount of CO 2 is flushed out of the airway. 5 Several studies have demonstrated that highflow oxygen can be beneficial during awake fiberoptic intubation, 9 pre-oxygenation before emergency tracheal intubation in critically ill patients 10 and in patients with intracranial haemorrhage. 11 Taken together, apnoeic oxygenation using THRIVE seems to be a feasible alternative for shorter laryngeal procedures and might also be a safe way to pre-oxygenate patients before and during tracheal intubation, thereby extending the apnoeic window. Notably, to date apnoeic oxygenation using THRIVE has only been demonstrated in a case series of 25 patients and systematic data on arterial blood gases during THRIVE are lacking. 5 The primary aim of the study was to investigate the changes in arterial oxygen, carbon dioxide and pH over time when THRIVE was used under general anaesthesia during short laryngeal procedures. The secondary aims were (1) to describe PaO 2 , PaCO 2 and pH after hyperventilation during pre-oxygenation, (2) to see whether transcutaneous carbon dioxide measurement is consistent with blood gas analysis and (3) to characterize the difference between ETCO 2 and PaCO 2 at the end of the procedure. 
Methods

Ethics
Study subjects
31 adult patients (>18 yr), ASA physical status I-II, presenting for elective short laryngeal procedures, such as microlaryngoscopy, were included in this prospective randomized trial. Participants were enrolled preoperatively by one of four anaesthetists responsible for data collection in the study. Exclusion criteria were ASA physical status >II, New York Heart Association class >2, body mass index (BMI) > 30, pregnancy, severe gastrointestinal reflux disease and neuromuscular disease. Patients were included after oral and written informed consent.
Monitoring
Standard perioperative monitoring including non-invasive blood pressure (NIBP), 3-lead ECG and peripheral oxygen saturation (SpO 2 ) (Aisys CS, GE Healthcare, United States) was used throughout the procedure. The patients received an arterial line in the radial artery before induction of anaesthesia and arterial blood gases were obtained before pre-oxygenation and every five min after anaesthesia induction. Blood gases were analysed using an ABL 90 (Radiometer, Brønshøj, Denmark). Transcutaneous carbon dioxide (tcCO 2 ) was continuously monitored (Radiometer, Brønshøj, Denmark) with the sensor placed on the left part of the chest after calibration. End-tidal carbon dioxide (ETCO 2 ) was measured before pre-oxygenation during spontaneous breathing and on the first breath at end of apnoea. The degree of neuromuscular block was assessed by the train-of-four (TOF) ratio (Aisys CS, GE Healthcare, United States) with the neuromuscular transmission monitor placed over the ulnar nerve measuring adductor pollicis muscle activity.
Study protocol
Patients were placed in a supine position with the head elevated approximately 10-20 degrees and received a peripheral venous cannula. Ringer-acetate solution (Ringer-AcetatV R , Baxter Healthcare Ltd, Thetford Norfolk, Great Britain) was given perioperatively. Of the pre-planned 30 patients, the first 20 patients were randomized into two blocks of 10 subjects each to preoxygenation with or without hyperventilation using a randomization plan from http://www.randomization.com (last accessed November 19, 2015 was put in place in full suspension, ensuring that the dorsal part of the laryngeal inlet was open to oxygen flow at all times. During the procedure blood-gas analyses were assessed every five min. TcCO 2 , ECG, arterial BP and SpO 2 were measured continuously. Neuromuscular block was monitored with a TOF ratio registered every five min throughout the procedure with a mean TOF ratio of 6.0 (12.7) % during apnoea. Reversal was done with a fixed dose of 200 mg of sugammadex (BridionV R , MSD, Hertfordshire, Great Britain), which was enough to reverse the neuromuscular block to a TOF ratio >90%. At the end of the procedure the airway was repossessed by the anaesthetist and the patient was mask ventilated until spontaneous breathing reoccurred. ETCO 2 was measured on the first breath at end of apnoea when ventilated with a mask or a tracheal tube if intubated because of discontinuation criteria below. The apnoeic time was until the procedure was completed or until a discontinuation criterium occurred. Discontinuation criteria were a procedure duration > 40 min, PaCO 2 > 11 kPa, pH <7.15, SpO 2 <90% or occurrence of malignant arrhythmias. If any of the criteria was fulfilled the apnoeic period was ended by intubation with a tracheal tube and ventilated mechanically or jet ventilated.
Postoperatively patients were monitored with non-invasive BP, ECG and SpO 2 . Blood gases were analysed at admission and discharge. Participation in the study was concluded when the patient left the post-anaesthesia care unit (PACU).
Sample size calculation
The primary outcomes of this study are descriptive and therefore no power analysis was done on these and we planned for 30 patients to target the primary outcomes. Before study start, a power analysis for the effect of hyperventilation on the increase in PaCO 2 was designed to have a two-tailed alpha error of 0.05 and a beta error of 0.2 (power 80%). If the true difference between normoventilation and hyperventilation at 20 min was at least 1.5 kPa and a standard deviation of 1.0 kPa, a sample size of eight in each group was suggested. In order to compensate for dropouts we planned for 10 patients in each group.
Statistical analysis
Data are presented as mean (SD) or range and pre-planned analysis was done using paired or un-paired Student's t-tests as appropriate when comparing two variables. As the duration of apnoea was different between the patients and the apnoeic time largely dependent on the surgery we decided to analyse the hyperventilation trial with an unpaired Student's t-test at the last point in time where all patients were in the trial (i.e. at 10 min). Statistical analysis and graphs were made using Prism 6.0 and Statmate 2 (GraphPad, Software Inc., La Jolla, CA, USA). A P-value of <0.05 was considered statistically significant.
Results
Study population
Thirty patients completed the study protocol (CONSORT flow diagram, Appendix 2). One patient was excluded from the study because of obstruction of the nasal catheter by the laryngoscope used during surgery. For two patients the pre-operative blood gas is missing as a result of technical difficulties. Patient characteristics data is presented in Table 1 .
The apnoeic time was 22.5 (4.5) min. In one patient the surgery was not finished when PaCO 2 was 11 kPa (discontinuation criteria), therefore supraglottic jet ventilation was initiated. For all other patients apnoea was terminated because surgery was finished. The study was terminated as planned when 30 participants had completed the protocol.
Primary outcome: changes in PaO 2, , PaCO 2 and pH All patients were well oxygenated throughout the procedure and none had a SpO 2 below 91% (Fig. 1) . A summary of apnoea times and corresponding PaO 2, and PaCO 2 values at the end of (0.04) to 7.14 (0.01) (Fig. 2C) . Base excess and bicarbonate are presented in Figure 3 .
Secondary outcomes
Hyperventilation The first 20 patients were randomized to normal breathing or hyperventilation during pre-oxygenation. Immediately after hyperventilation during pre-oxygenation tcCO 2 was 4.18 (0.82) kPa compared with the resting value before pre-oxygenation of 5.05 (1.00) kPa (P ¼ 0.0001), n ¼ 10. At five min tcCO 2 did not differ compared with those who normoventilated (Fig. 4C ). Therefore no difference in PaCO 2 and pH over time between the groups with or without hyperventilation during pre-oxygenation with Optiflow TM was seen (Fig. 4) .
Comparison between arterial and transcutaneous carbon dioxide There was no difference between tcCO 2 and PaCO 2 (Fig. 2B) .
Arterial-alveolar and end-tidal carbon dioxide difference before and after apnoeic oxygenation using THRIVE In 17 of the patients a preoperative ETCO 2 was measured and the difference between ETCO 2 and PaCO 2 was 0.73 (1.35) kPa preoperatively and increased to 3.11 (0.95) kPa (P < 0.0001) at the end of the procedure. The increase in ETCO 2 was 0.12 (0.04) kPa min À1 .
Circulatory effects A reduction of BP was observed during the first 10 min (Fig. 5) . The heart rate was stable during apnoea and no patients experienced arrhythmias except a few single ventricular extra systoles without effect on haemodynamics.
Subjective experience of the surgeon
The surgeons reported more favourable conditions for surgery using apnoeic oxygenation in all patients (n ¼ 30), compared with a traditional technique using tracheal tube, jet ventilation or apnoea combined with mask ventilation. 
Postoperative care
The peripheral oxygen saturation was 97 (1.8) % on arrival to PACU. No patient experienced desaturation below 91%. The PaO 2, was 13.6 (4.4) kPa at admission and 11.3 (1.9) kPa at discharge. The PaCO 2 was 5.79 (0.56) kPa at admission and 5.51 (0.43) kPa at discharge. All patients were routinely put on supplemental O 2 on transport from operation room to PACU and 13 patients received additional nasal oxygen of 1-3 litres min À1 in the PACU. All patients were haemodynamically stable. Mean length of stay in the PACU was 70 (28) min.
Discussion
In this prospective interventional trial we demonstrate that oxygenation during apnoea using THRIVE maintains the patients well oxygenated for up to 30 min with arterial pH of 7. 
Comparison with previous studies
The prerequisite for apnoeic oxygenation is that 100% oxygen is delivered in an airway that remains open and that full denitrogenation has been accomplished. Provided that those criteria have been fulfilled, oxygen saturation has been maintained for time periods as long as 65 min. 2 5 12 The limiting factor for the duration of apnoeic oxygenation is not oxygenation but rather increase in CO 2 and lowering of arterial pH. 2 6-8 12 13 CO 2 moves from the bloodstream into the alveoli by passive diffusion during apnoea, but is also buffered in the blood. The increase of PaCO 2 level varies between studies. In a study mimicking total airway occlusion, completely without CO 2 washout, an average increase of CO 2 of 0.68 kPa min À1 was seen. 8 Older studies of apnoeic oxygenation supplying a flow of oxygen of approximately 0.2 litres min À1 gave an average CO 2 increase between 0.43 and 0.56 kPa min
À1
. 2 6 7 Increasing the oxygen flow and delivering it endobronchially with thin catheters allowing for gas exchange outside of the lung resulted in a lower increase of CO 2 (0.24 kPa min THRIVE -evolvement of blood gases and pH over time | 615 transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) with Optiflow during apnoea with the goal of securing a difficult airway. With a high flow of oxygen of 70 litres min À1 delivered nasally CO 2 increased with a rate of 0.15 kPa min À1 measured by capnography. 5 In our study we had different rates of accumulation of CO 2 depending on the method of analysis, endtidal vs arterial and transcutaneous. As the gradient between ETCO 2 and PaCO 2 was increased over time capnography is clearly not a reliable method of monitoring during extended apnoea. More importantly, capnography cannot be used during apnoeic oxygenation.
In both studies the airway was kept patent at all times, but in the present study partial blocking of the laryngeal inlet created by the surgeon's tubular laryngoscope could potentially affect the mass flow of gas. As we had the same increase in ETCO 2 as in the above mentioned study, gasflow around the tubular laryngoscope seems to be sufficient. Muscle activity of the diaphragm and minimal movements can eliminate CO 2 during apnoea. Therefore we aimed for full muscle relaxation and close monitoring, making sure the patients were truly apnoeic the entire study period. Blocking muscular action could lower the production of CO 2 from skeletal muscle, 14 while minimal recovery of neuromuscular transmission resulting in spontaneous ventilation might enhance CO 2 clearance. Both administration and monitoring of neuromuscular activity have varied in previous studies.
2 6-8 12 13 The increase of CO 2 during THRIVE in the current study presents a non-linear pattern with an initial quick increase of the CO 2 that levelled off during the apnoeic period, as has been described in previous studies. 6 8 15 The exact mechanism behind this is not fully understood. Hyperventilation had a limited and brief effect of lowering the PaCO 2 but could not substantially affect PaCO 2 to prolong the apnoeic window.
Transcutaneous CO 2 showed good correlation to arterial CO 2 with no detectable difference, which is in line with other studies. 16 The high flow of oxygen delivered by Optiflow TM provides a slight positive airway pressure 17 18 that could increase functional residual capacity, 19 prevent atelectasis caused by anaesthesia and apnoea 20 and improve gas exchange. Despite this, we noted an increased arterial-alveolar CO 2 difference during the apnoeic period.
Study strengths and limitations
Repeated systematic arterial blood gas sampling during apnoeic oxygenation with THRIVE was done for the first time and correlated to tcCO 2 which might be more convenient for use in a clinical situation.
Only non-obese patients of ASA class I-II were included. The conclusions may therefore not be applicable to patients with obesity or advanced cardiopulmonary disease. Randomization in the present study was done regarding hyperventilation, but was not blinded to the examiner.
Clinical relevance and direction of future studies
The present study demonstrates that apnoeic oxygenation using THRIVE could act as an alternative to conventional ventilation techniques during short time laryngeal surgery. Potential clinical advantages using THRIVE during laryngeal surgery are higher accessibility to the operating field and less vibrations than caused by jet ventilation.
Based on this study, it is likely that the THRIVE technique could be applied to extend the time to desaturation in other situations (i.e. emergencies). As we have only studied ASA I-II patients with a BMI below 30, it is of importance to evaluate this technique in patients with more pronounced systemic disease and more importantly a higher BMI. There are older data indicating that a higher BMI, often associated with a lower functional residual capacity, shortens the time to desaturation during apnoea, 21 but this has not been investigated using THRIVE. Also, if there is a substantial V/Q mismatch present, even a high flow of oxygen during apnoea will not be enough to counteract hypoxia. 22 Moreover, much is still unknown regarding the basic physiology of THRIVE. The effects of a progressive increase of CO 2 and acidosis using THRIVE regarding other organs of the body and toxic effects of hyperoxia need to be further evaluated. Finally, the airway pressure, flow mechanics and mechanism for CO 2 washout remain to be described. 
